PHATHOM PHARMACEUTICALS, INC. (PHAT) Spending and interest coverage
- R&D / revenue · 12 months: Value 12.56%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 11.33%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 12.56% | Research and development expense / revenue. Period ending 2026-06-30. $30.11M ÷ $239.66M × 100 ≈ 12.56% |
| Stock-based compensation / revenue · 12 months | 11.33% | Share-based compensation / revenue. Period ending 2026-06-30. $27.15M ÷ $239.66M × 100 ≈ 11.33% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 30.11M USD | Research and Development Expense |
| Revenue | 239.66M USD | |
| Stock-based compensation | 27.15M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -40.64M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $30.11M | $239.66M | $27.15M | $-40.64M | (m) | 12.56% | 11.33% | (m) | (m) |
| 2026-03-31 | $31.37M | $204.89M | $28.71M | $-96.60M | (m) | 15.31% | 14.01% | (m) | (m) |
| 2025-12-31 | $32.78M | $175.11M | $28.72M | $-159.99M | (m) | 18.72% | 16.40% | (m) | (m) |
| 2025-09-30 | $33.87M | $147.19M | $29.80M | $-213.47M | (m) | 23.01% | 20.24% | (m) | (m) |
| 2025-06-30 | $35.54M | $114.04M | $26.13M | $-269.00M | (m) | 31.16% | 22.92% | (m) | (m) |
| 2025-03-31 | $33.84M | $81.86M | $23.96M | $-286.38M | (m) | 41.33% | 29.27% | (m) | (m) |
| 2024-12-31 | $34.08M | $55.25M | $24.05M | $-277.47M | (m) | 61.68% | 43.52% | (m) | (m) |
| 2024-09-30 | $38.89M | $26.27M | $41.94M | $-287.93M | (m) | 148.05% | 159.67% | (m) | (m) |
| 2024-06-30 | $42.46M | $9.92M | $42.45M | $-252.79M | $58.07M | 428.14% | 428.00% | -4.35× | Reported |
| 2024-03-31 | $47.85M | $2.59M | $43.60M | $-207.19M | $49.92M | 1844.64% | 1680.92% | -4.15× | Reported |
| 2023-12-31 | $49.90M | $682.00K | $45.02M | $-167.31M | $41.97M | 7316.57% | 6601.91% | -3.99× | Reported |
| 2023-09-30 | $52.45M | (m) | $27.10M | $-144.08M | $38.54M | (m) | (m) | -3.74× | Reported |
| 2023-06-30 | $59.21M | (m) | $26.77M | $-150.95M | $37.71M | (m) | (m) | -4.00× | Reported |
| 2023-03-31 | $65.26M | (m) | $25.41M | $-164.61M | $33.76M | (m) | (m) | -4.88× | Reported |
| 2022-12-31 | $71.44M | (m) | $24.13M | $-172.44M | $27.30M | (m) | (m) | -6.32× | Reported |
| 2022-09-30 | $69.05M | (m) | $21.81M | $-158.84M | $20.48M | (m) | (m) | -7.76× | Reported |
| 2022-06-30 | $66.64M | (m) | $20.42M | $-149.45M | $12.69M | (m) | (m) | -11.78× | Reported |
| 2022-03-31 | $69.42M | (m) | $18.77M | $-139.40M | $8.28M | (m) | (m) | -16.85× | Reported |
| 2021-12-31 | $72.34M | (m) | $16.81M | $-135.08M | $6.79M | (m) | (m) | -19.90× | Reported |
| 2021-09-30 | $100.44M | (m) | $14.85M | $-154.48M | $5.31M | (m) | (m) | -29.10× | Reported |
| 2021-06-30 | $109.60M | (m) | $12.50M | $-154.17M | $5.11M | (m) | (m) | -30.18× | Reported |
| 2021-03-31 | $102.86M | (m) | $9.10M | $-138.87M | $5.12M | (m) | (m) | -27.15× | Reported |
| 2020-12-31 | $98.15M | (m) | $5.84M | $-125.67M | $4.58M | (m) | (m) | -27.43× | Reported |
| 2020-09-30 | $69.20M | (m) | $3.80M | $-88.92M | $4.33M | (m) | (m) | -20.56× | Reported |
| 2020-06-30 | $47.90M | (m) | $1.77M | $-62.37M | $5.03M | (m) | (m) | -12.40× | Reported |
| 2020-03-31 | $35.81M | (m) | (m) | $-125.36M | $4.90M | (m) | (m) | -25.56× | Reported |
| 2019-12-31 | $20.37M | (m) | $406.00K | $-106.22M | $4.18M | (m) | (m) | -25.43× | Reported |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $3.22M | (m) | (m) | $-84.96M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | $-2.20M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $20.00K | (m) | (m) | $-1.23M | $13.00K | (m) | (m) | -94.23× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |